Deletion and inactivating mutations of pRb are restricted to very few specific cancer types, whereas alterations of p107 and/or p130 in human cancers is still a matter of debate, being rarely mutated in human tumors (70, 71), probably due to pRb controls E2F activity in a broad manner (72). This evidence concerns the gene RBL2 and cancer.